Video

Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer

Author(s):

Mary Jo Fidler, MD

In Partnership With:

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non—small cell lung cancer.

In a phase III trial, there was a clear benefit of osimertinib when compared with standard frontline platinum doublet chemotherapy in patients who progressed on a first-generation TKI.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Related Content
Benjamin Herzberg, MD
October 29th 2024

IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Noman Ashraf, MD
October 23rd 2024

ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Hidehito Horinouchi, MD, PhD
October 18th 2024

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC

Myung-Ju Ahn, MD, PhD, professor, hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
October 16th 2024

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC